United States Drug Patent 8,614,178: Claim Scope, Expiration, Orange Book Status, and Competitive Landscape

U.S. Patent No. 8,614,178 protects ophthalmic compositions containing a macrolide immunosuppressant, particularly ciclosporin A, dissolved in a semifluorinated alkane. The strongest commercial embodiment is a clear, substantially water-free solution containing approximately 0.01% to 0.5% ciclosporin A in F4H5, also known as perfluorobutylpentane. The patent is directed to composition and kit claims rather than a treatment method, manufacturing process, or device claim.

The patent is highly relevant to water-free ciclosporin products for dry-eye disease, including VEVYE, a ciclosporin ophthalmic solution approved by the U.S. Food and Drug Administration in 2023. Its practical value depends on the asserted patent family, Orange Book listing, continuation patents, terminal disclaimers, patent-term adjustment, and any license or settlement arrangements involving the commercial product.

What does U.S. Patent 8,614,178 protect?

U.S. Patent 8,614,178 covers a pharmaceutical composition comprising two required elements:

A therapeutically effective macrolide immunosuppressant useful for keratoconjunctivitis sicca or an associated symptom.
A liquid vehicle containing a semifluorinated alkane.

The composition must be formulated as a clear solution under independent claim 1. Claim 10 adds a separate composition category that expressly requires ethanol.

The patent does not broadly cover every ciclosporin eye drop. It targets a particular formulation architecture: a poorly water-soluble immunosuppressant dissolved in a semifluorinated alkane, preferably without water.

Claim feature	Scope
Active ingredient	Macrolide immunosuppressant useful for dry-eye treatment
Preferred active	Ciclosporin A
Active concentration	About 0.01 wt.% to about 0.5 wt.%
Vehicle	Semifluorinated alkane
Preferred vehicle class	RFRH or RFRHRF compounds
Preferred compounds	F4H5, F4H6, F6H6 and F6H8
Narrowest named vehicle	F4H5
Physical form	Clear solution
Water limitation	Effectively free of water in claim 8
Cosolvent option	Organic cosolvent under claim 9
Ethanol embodiment	Required by claim 10; approximately 1 wt.% or less under claim 11
Delivery format	Ophthalmic kit with an eye-dispensing container under claim 12

The patent specification identifies semifluorinated alkanes as liquids containing a perfluorinated segment and a hydrocarbon segment. The fluorinated portion contributes chemical and physical properties distinct from conventional aqueous or oil-based ophthalmic vehicles. The claims use the structural definitions RF and RH rather than limiting the invention exclusively to a commercial product name. (U.S. Patent No. 8,614,178, claims 1-13.)

How broad is claim 1 of U.S. Patent 8,614,178?

Claim 1 is the principal broad composition claim. It has four material limitations:

A therapeutically effective macrolide immunosuppressant.
Usefulness for preventing or treating keratoconjunctivitis sicca or a related symptom.
A liquid vehicle containing a semifluorinated alkane.
A clear-solution formulation.

The claim does not require ciclosporin A, a specific concentration, F4H5, complete absence of water, or ethanol. Those limitations appear in dependent claims or in the separate claim 10 series.

The term “selected from the group of macrolide immunosuppressants” is potentially broader than ciclosporin A. Depending on the specification and prosecution history, the group may encompass other macrolide immunosuppressants capable of the claimed ophthalmic use. Ciclosporin A is separately narrowed in claim 3.

The “clear solution” limitation is important. A suspension, emulsion, opaque dispersion, or visibly particulate formulation would present a non-infringement argument if the product does not meet the ordinary technical meaning of a clear solution. The limitation also distinguishes the claimed formulation from conventional ciclosporin ophthalmic emulsions.

What is the narrowest and commercially most relevant claim?

Claim 13 is the narrowest named embodiment:

Ciclosporin A;
a semifluorinated alkane within the linear RFRH class;
F4H5 as the specified vehicle.

Claim 13 depends through claim 6 and therefore incorporates the linear perfluorinated and linear alkyl segment requirements. It is narrower than claim 3, which requires ciclosporin A but does not specify the vehicle.

Claim 4 narrows ciclosporin A to approximately 0.01 wt.% to 0.5 wt.%. A product containing 0.1% ciclosporin A falls within that stated concentration range, assuming the other limitations are met. VEVYE is labeled as cyclosporine ophthalmic solution 0.1%, which makes the concentration limitation commercially relevant. (FDA, 2023a.)

What are the key dependent claims?

Claims 2 through 4: poorly water-soluble active and ciclosporin concentration

Claim 2 requires an active ingredient with water solubility below approximately 1 mg/mL at room temperature and neutral pH. Claim 3 identifies ciclosporin A. Claim 4 specifies approximately 0.01 wt.% to 0.5 wt.% ciclosporin A.

These claims create a fallback sequence:

Claim 1: broad active and vehicle concept.
Claim 2: poorly water-soluble active.
Claim 3: ciclosporin A.
Claim 4: ciclosporin A at a defined concentration range.

The solubility test language may create factual disputes over temperature, pH, measurement method, polymorphic form, and whether the accused formulation is evaluated before or after dilution or administration.

Claims 5 through 7: semifluorinated alkane structure

Claim 5 defines the vehicle as either RFRH or RFRHRF. RF is a perfluorinated hydrocarbon segment with no more than 20 carbon atoms. RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon atoms.

Claim 6 narrows the structure to an RFRH compound with:

A linear RF segment containing 3 to 10 carbon atoms.
A linear alkyl RH group containing 3 to 10 carbon atoms.

Claim 7 identifies F4H5, F4H6, F6H6 and F6H8. Claim 13 further selects F4H5.

This structure-based drafting is significant because literal infringement may turn on the identity and connectivity of the vehicle rather than on the product’s trade name. A product using a chemically different fluorinated solvent may avoid literal infringement while still raising an equivalents issue.

Claims 8 and 9: water and cosolvents

Claim 8 requires the composition to be effectively free of water. This limitation supports a distinction from aqueous ciclosporin formulations and from emulsions containing a substantial aqueous phase.

Claim 9 permits an organic cosolvent. The claim does not specify a concentration or identify a particular cosolvent. Ethanol is addressed separately in claim 10, with claim 11 limiting ethanol to approximately 1 wt.% or less.

Claims 10 and 11: ethanol-containing compositions

Claim 10 is an independent composition claim requiring:

The macrolide immunosuppressant;
The semifluorinated alkane vehicle; and
Ethanol.

Claim 11 narrows ethanol to approximately 1 wt.% or less. A formulation without ethanol cannot infringe claim 10 or claim 11, although it may still fall within claim 1 or another claim.

Claim 12: pharmaceutical kit

Claim 12 covers a kit containing the composition of claim 1 and a container with dispensing means adapted for topical administration to the eye.

The claim introduces container-level limitations. A bulk formulation without the claimed ophthalmic dispensing container would not necessarily satisfy the kit claim. The kit claim is commercially relevant because unit-dose and multidose ophthalmic packaging may be sold together with the formulation.

What is the patent expiration date for U.S. Patent 8,614,178?

U.S. Patent 8,614,178 issued on December 24, 2013. Its patent term is governed by the Uruguay Round Agreements Act term rules, generally extending 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable prosecution history.

Public patent records associate the patent with a priority chain dating to the late 2000s. On that basis, the ordinary term is expected to run into 2027, subject to the precise effective filing date and the patent-term adjustment shown in the USPTO record. The legally operative expiration date should be taken from the USPTO Patent Center record and any Orange Book patent-term information rather than inferred solely from the issue date. (USPTO, 2013; USPTO, 2024.)

A patent expiration in 2027 would not by itself establish immediate generic entry. A competing product may remain exposed to later-expiring continuation patents, formulation patents, use patents, or regulatory exclusivity.

What is the Orange Book status of U.S. Patent 8,614,178?

The Orange Book question is product-specific. A patent may be relevant to an approved product without being listed against every drug containing the same active ingredient.

For VEVYE, the relevant regulatory product is cyclosporine ophthalmic solution 0.1%, approved under NDA 217023. The FDA approval concerns a non-aqueous ophthalmic solution for dry-eye disease, materially corresponding to the formulation category claimed in the patent. The FDA Orange Book should be reviewed for:

Whether U.S. Patent 8,614,178 is listed against NDA 217023;
The listed use code;
Any patent expiration date entered by the sponsor;
Later-issued patents listed against the same NDA;
Whether the listing covers the formulation, an approved method of use, or both.

The Orange Book does not itself decide infringement or validity. A listed patent can be challenged through an ANDA Paragraph IV certification, and a patent omitted from the Orange Book may still create litigation risk under other legal theories. (FDA, 2024a; FDA, 2024b.)

When does VEVYE lose exclusivity?

VEVYE received FDA approval in May 2023. Because ciclosporin is an established active ingredient, the product did not receive five-year new chemical entity exclusivity. FDA approval of a new dosage form, formulation, or clinical indication can support three years of marketing exclusivity when the application contains new clinical investigations conducted or sponsored by the applicant and essential to approval.

The practical exclusivity timetable therefore has two separate components:

Exclusivity or protection	Likely relevance to VEVYE
New chemical entity exclusivity	Not expected because ciclosporin was previously approved
Three-year clinical-investigation exclusivity	Potentially relevant, subject to FDA’s specific exclusivity determination
Patent protection	Potentially extends into the late 2020s for the foundational formulation patent
Continuation or improvement patents	May extend protection beyond the foundational patent
Pediatric exclusivity	No conclusion should be drawn without an FDA-listed pediatric extension
Orphan exclusivity	Not expected for the dry-eye indication

FDA regulatory exclusivity and patent term operate independently. A generic applicant may be unable to obtain final approval during applicable FDA exclusivity even if it can challenge a patent. Conversely, a patent may remain enforceable after FDA exclusivity expires.

Which companies are challenging U.S. Patent 8,614,178?

No reliable conclusion that a specific company has filed a Paragraph IV challenge to this patent should be drawn without a current FDA Orange Book, ANDA litigation, or district-court record. Publicly visible market activity has not established a broadly reported generic launch against VEVYE comparable to the major generic challenges involving older high-volume ophthalmic products.

A Paragraph IV challenge would ordinarily involve:

An ANDA applicant certifying that the listed patent is invalid, unenforceable, or not infringed.
Notice to the NDA holder and patent owner.
A potential Hatch-Waxman action within 45 days.
A 30-month stay of FDA approval if statutory conditions are met.

A 180-day generic exclusivity period would apply only if a first applicant qualifies under the applicable ANDA rules. No biosimilar pathway applies because ciclosporin is a chemically defined small molecule, not a biologic.

How strong is the patent estate for semifluorinated-alkane ciclosporin?

The foundational patent has meaningful claim value because it captures the combination of:

A known dry-eye active;
A nonconventional semifluorinated vehicle;
A clear solution;
Low-water or water-free formulation options; and
A commercially practical 0.1% ciclosporin concentration.

Its principal vulnerabilities are claim construction and design-around opportunities. A challenger could attack:

Written description or enablement for the full genus of macrolide immunosuppressants and semifluorinated alkanes;
Obviousness based on prior art describing ciclosporin, dry-eye treatment, fluorinated solvents, and ophthalmic delivery;
The meaning of “clear solution”;
The meaning of “effectively free of water”;
The accuracy and reproducibility of the water-solubility limitation;
Whether the accused product contains the claimed RF/RH structural segments;
Whether the vehicle is present as a liquid vehicle in the claimed sense.

The narrow F4H5 and ciclosporin claims are easier to map to a product with the same formulation but have a smaller technical scope. The broader claim 1 has greater blocking potential but may face a more substantial validity challenge.

What formulations are protected compared with older ciclosporin products?

The patent distinguishes semifluorinated-alkane solutions from conventional ciclosporin products.

Product or formulation type	Vehicle architecture	Relation to U.S. 8,614,178
Restasis	Aqueous emulsion containing cyclosporine 0.05%	Generally outside the claimed semifluorinated-alkane vehicle limitation
Cequa	Cyclosporine ophthalmic solution 0.09% using a nanomicellar formulation	Requires separate analysis; does not inherently satisfy the semifluorinated-alkane limitation
VEVYE	Cyclosporine ophthalmic solution 0.1% in a semifluorinated-alkane vehicle	Closely aligned with the claimed formulation architecture
Generic aqueous or emulsion ciclosporin	Conventional aqueous, emulsion, or micellar systems	Usually outside the core vehicle limitation
Future fluorinated-solvent product	Depends on RF/RH structure, concentration, clarity, active, and packaging	May present direct or equivalents exposure

The patent therefore does not block the entire ciclosporin ophthalmic market. It is most relevant to products using the same or a structurally related semifluorinated solvent platform.

What patent litigation and licensing issues affect the commercial landscape?

The principal commercial issue is the relationship between the patent family and the marketed product. VEVYE is based on the CyclASol development program associated with Novaliq’s semifluorinated-alkane technology. Commercial rights and U.S. commercialization arrangements have involved Novaliq and later commercial partners, including Harrow-related commercialization activity. The exact scope of each license, patent assignment, royalty obligation, and enforcement right must be determined from the executed agreements and USPTO assignment records.

Relevant diligence questions include:

Whether the patent was assigned from the original applicant to the current patent owner;
Whether the NDA holder has an exclusive license;
Whether the license covers only the United States or global rights;
Whether the license includes continuation and divisional patents;
Whether there are prosecution-control or enforcement provisions;
Whether any settlement restricts generic development;
Whether later patents claim the same product, manufacturing process, or approved indication.

No settlement agreement or Paragraph IV resolution should be treated as established without a filed court document, FDA record, SEC disclosure, or other primary source.

How does U.S. Patent 8,614,178 compare with later formulation patents?

U.S. 8,614,178 is a platform composition patent. Later patents may have greater commercial leverage if they claim:

A specific ciclosporin concentration;
A named semifluorinated alkane such as F4H5;
A defined viscosity or osmolality;
A particular preservative-free multidose container;
Droplet size or delivery performance;
A specific dosing schedule;
A method of treating dry-eye disease;
A manufacturing process that produces the commercial product.

A later patent can remain enforceable after U.S. 8,614,178 expires. For generic-entry analysis, the relevant blocking date is the latest valid and enforceable patent that the ANDA product would infringe, not necessarily the expiration date of the earliest platform patent.

What generic launch scenarios exist for VEVYE?

Launch before foundational patent expiration

A pre-expiration launch would require one of four outcomes:

A successful Paragraph IV invalidity or non-infringement case;
A license from the patent owner;
A settlement permitting an agreed launch date;
A product design-around that avoids all relevant listed and unlisted patent claims.

Launch at foundational patent expiration

A 2027 expiration scenario could permit entry if no later patent blocks the product and FDA exclusivity has expired. A generic would still need to satisfy the applicable ophthalmic product requirements, including pharmaceutical equivalence, bioequivalence or applicable alternative evidence, sterility, container closure, and chemistry, manufacturing, and controls requirements.

Design-around launch

A competitor could avoid the core patent by using:

An aqueous emulsion;
A micellar solution;
A different nonfluorinated vehicle;
A fluorinated vehicle outside the claimed RF/RH structures;
A suspension rather than a clear solution;
A different active ingredient or concentration.

Each design-around may create separate clinical, formulation, delivery, or patent risks.

Does biosimilar risk apply to this patent?

No. Biosimilar risk does not apply directly because ciclosporin is a small-molecule immunosuppressant. The relevant competitors would file ANDAs or, in some circumstances, 505(b)(2) applications. A 505(b)(2) applicant may rely partly on FDA’s prior findings while addressing formulation or clinical differences, but it remains exposed to applicable listed patents and regulatory exclusivity.

What is the geographic coverage of U.S. Patent 8,614,178?

The patent provides rights only in the United States. Equivalent protection must be assessed separately in each jurisdiction. The relevant international family may include European and other national applications directed to semifluorinated-alkane pharmaceutical compositions.

Geographic diligence should cover:

U.S. patent term and Orange Book listing;
European Patent Office status;
National phase grants and expirations;
Patent-term extensions or supplementary protection certificates;
Assignment and licensing records;
Local litigation and opposition proceedings.

A U.S. invalidity decision would not automatically eliminate corresponding foreign rights.

Key Takeaways

U.S. Patent 8,614,178 claims clear ophthalmic solutions containing a macrolide immunosuppressant in a semifluorinated alkane.
Ciclosporin A is expressly claimed, including concentrations of approximately 0.01% to 0.5%.
F4H5 is the most commercially important named vehicle and is expressly covered by claim 13.
Claims 8 through 11 address water-free, cosolvent, and low-ethanol embodiments.
Claim 12 extends protection to an ophthalmic dispensing kit.
The patent issued on December 24, 2013, and its ordinary term is expected to extend into the late 2020s, subject to USPTO term calculations.
VEVYE is the principal FDA-approved product aligned with the claimed formulation concept.
Generic risk is an ANDA issue, not a biosimilar issue.
The principal competitive threat is a generic or 505(b)(2) product using a noninfringing vehicle or a successful Paragraph IV challenge.
Later formulation, method-of-use, packaging, or manufacturing patents may control entry after the foundational patent expires.
Current Orange Book and USPTO records are necessary to determine the operative listed-patent set and final expiration dates.

FAQs About U.S. Patent 8,614,178

Is U.S. Patent 8,614,178 a patent on ciclosporin itself?

No. It does not claim ciclosporin as a chemical compound. It claims pharmaceutical compositions containing ciclosporin or another qualifying macrolide immunosuppressant in a semifluorinated-alkane vehicle.

Does Restasis infringe U.S. Patent 8,614,178?

Restasis uses an aqueous emulsion rather than the claimed semifluorinated-alkane vehicle. On the formulation information publicly associated with Restasis, it does not match the core vehicle limitation.

Can a generic use a different fluorinated solvent?

Potentially. The solvent would need to be evaluated against the structural RF/RH limitations, the clear-solution requirement, the active-ingredient limitations, and any later patents. A different trade name alone does not establish non-infringement.

Is F4H5 the same as perfluorobutylpentane?

F4H5 is the shorthand used in the patent’s semifluorinated-alkane nomenclature for a compound containing a four-carbon perfluorinated segment and a five-carbon hydrocarbon segment. Commercial chemical identity and nomenclature should be confirmed against the product’s chemistry and regulatory documentation.

Does patent expiration automatically permit generic VEVYE approval?

No. FDA exclusivity, later-listed patents, formulation differences, manufacturing requirements, sterility obligations, and any litigation or settlement restrictions can affect the timing of approval and launch.

References

U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,614,178, Pharmaceutical compositions comprising semifluorinated alkanes.
U.S. Food and Drug Administration. (2023a). VEVYE (cyclosporine ophthalmic solution) 0.1% prescribing information.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (2024b). Approved drug product patent and exclusivity information.
U.S. Patent and Trademark Office. (2024). Patent Center and patent-term information resources.
U.S. Food and Drug Administration. (2023b). VEVYE approval letter for NDA 217023.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	VEVYE	cyclosporine	SOLUTION;OPHTHALMIC	217469-001	May 30, 2023		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010333039	⤷ Start Trial
Brazil	112012014190	⤷ Start Trial
Brazil	122017018955	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,614,178

Which drugs does patent 8,614,178 protect, and when does it expire?

Summary for Patent: 8,614,178